1000802-50-5

Upstream product

• 1309960-92-6 1-[3-(benzyloxy)propyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 925180-06-9 3-(4-bromo-1H-pyrazol-1-yl)propan-1-ol 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1380303-05-8 2-amino-N,N-diethyl-5-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]benzamide 
• 1380303-58-1 diethyl (4-{[4-({5-fluoro-4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-(methylcarbamoyl)phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate 

Relevant academic research and scientific papers

NEW MACROCYCLIC LRRK2 KINASE INHIBITORS

Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.

MACROCYCLIC KINASE INHIBITORS

Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial.

2,6-DIOXO-1,2,3,6-TETRAHYDROPYRIMIDINE-4-CARBOXAMIDES

Disclosed are sEH inhibitors of formula (I), wherein the variables are as defined herein, as well as pharmaceutical compositions, kits, and articles of manufacture that contain such compounds. Also disclosed are methods and intermediates for making the compounds and the use of such compounds to treat various disorders, diseases, and conditions associated with sEH.